| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.24 | 4e-11 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.23 | 7e-11 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.22 | 3e-10 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.21 | 5e-10 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.19 | 7e-10 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-09 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.21 | 7e-09 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.19 | 8e-09 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-08 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-08 |